2023 Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸ : 2023-03-25
±³À°ÀÏÀÚ : 2023-03-25
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ Á¦2 ȸÀÇÀå 321~322È£
±³À°ÁÖÁ¦ : 2023 Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç¥ÀûÄ¡·á¿¬±¸È¸
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ : kalc@lungca.or.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000¿ø/ ºñȸ¿ø 70,000¿ø ÇöÀåµî·Ï ȸ¿ø: 60,000¿ø/ ºñȸ¿ø 80,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 13:00~13:20 Patritumab Deruxtecan (PDx) °´ÙÇö(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 13:20~13:40 Trastuzumab Deruxtecan (Enhertu) ±è¹ÌÇö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 13:40~14:00 Amivantamab °û¼¼Çö(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 14:00~14:20 Coffee break ()
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 14:20~14:40 Heavy particle treatment in lung cancer Á¶¿¬¾Æ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 14:40~15:00 Combination with proton ǥȫ·Ä(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 15:00~15:20 CCRT with LINAC Á¤À¯¸®(¿ø±¤ÀÇ´ë)
ÈÞ½Ä 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 15:20~15:40 Coffee break ()
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 15:40~16:10 Utility of liquid biopsy in the management of aNSCLC Suyog Jain(Guardant healthcare)
±³À°½Ã°£ 03-25 ºÎ»ê º¤½ºÄÚ Á¦2ȸÀÇÀå 321È£-322È£ 16:10~16:40 IMBDx ÀÌ°æ¾Æ(¿¬¼¼ÀÇ´ë)